141 related articles for article (PubMed ID: 35986838)
1. Pimitespib: First Approval.
Hoy SM
Drugs; 2022 Sep; 82(13):1413-1418. PubMed ID: 35986838
[TBL] [Abstract][Full Text] [Related]
2. Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors.
Doi T; Yamamoto N; Ohkubo S
Future Oncol; 2024 Mar; 20(9):507-519. PubMed ID: 38050698
[TBL] [Abstract][Full Text] [Related]
3. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
Kurokawa Y; Honma Y; Sawaki A; Naito Y; Iwagami S; Komatsu Y; Takahashi T; Nishida T; Doi T
Ann Oncol; 2022 Sep; 33(9):959-967. PubMed ID: 35688358
[TBL] [Abstract][Full Text] [Related]
4. Pimitespib is effective on cecal GIST in a mouse model of familial GISTs with KIT-Asp820Tyr mutation through KIT signaling inhibition.
Kihara T; Yuan J; Watabe T; Kitajima K; Kimura N; Ohkouchi M; Hashikura Y; Ohkubo S; Takahashi T; Hirota S
Exp Mol Pathol; 2021 Dec; 123():104692. PubMed ID: 34606780
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors.
Li CF; Huang WW; Wu JM; Yu SC; Hu TH; Uen YH; Tian YF; Lin CN; Lu D; Fang FM; Huang HY
Clin Cancer Res; 2008 Dec; 14(23):7822-31. PubMed ID: 19047110
[TBL] [Abstract][Full Text] [Related]
6. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
[TBL] [Abstract][Full Text] [Related]
7. Avapritinib: First Approval.
Dhillon S
Drugs; 2020 Mar; 80(4):433-439. PubMed ID: 32100250
[TBL] [Abstract][Full Text] [Related]
8. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol.
Millson SH; Truman AW; Rácz A; Hu B; Panaretou B; Nuttall J; Mollapour M; Söti C; Piper PW
FEBS J; 2007 Sep; 274(17):4453-63. PubMed ID: 17681020
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
Wagner AJ; Chugh R; Rosen LS; Morgan JA; George S; Gordon M; Dunbar J; Normant E; Grayzel D; Demetri GD
Clin Cancer Res; 2013 Nov; 19(21):6020-9. PubMed ID: 24045182
[TBL] [Abstract][Full Text] [Related]
10. Ripretinib: First Approval.
Dhillon S
Drugs; 2020 Jul; 80(11):1133-1138. PubMed ID: 32578014
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells.
Dong Y; Liang C; Zhang B; Ma J; He X; Chen S; Zhang X; Chen W
Cancer Lett; 2015 May; 361(1):137-46. PubMed ID: 25737303
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
[TBL] [Abstract][Full Text] [Related]
13. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
Floris G; Debiec-Rychter M; Wozniak A; Stefan C; Normant E; Faa G; Machiels K; Vanleeuw U; Sciot R; Schöffski P
Mol Cancer Ther; 2011 Oct; 10(10):1897-908. PubMed ID: 21825009
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors.
Mariño-Enríquez A; Ou WB; Cowley G; Luo B; Jonker AH; Mayeda M; Okamoto M; Eilers G; Czaplinski JT; Sicinska E; Wang Y; Taguchi T; Demetri GD; Root DE; Fletcher JA
Oncogene; 2014 Apr; 33(14):1872-6. PubMed ID: 23584476
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of heat shock protein 90 isoforms in small cell lung cancer.
Lee JH; Kang KW; Kim JE; Hwang SW; Park JH; Kim SH; Ji JH; Kim TG; Nam HY; Roh MS; Lee EH; Park MI; Kim MS; Lee HW
Int J Clin Exp Pathol; 2015; 8(8):9487-93. PubMed ID: 26464709
[TBL] [Abstract][Full Text] [Related]
16. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
[TBL] [Abstract][Full Text] [Related]
17. HSP90alpha and HSP90beta isoforms selectively modulate MHC class II antigen presentation in B cells.
Houlihan JL; Metzler JJ; Blum JS
J Immunol; 2009 Jun; 182(12):7451-8. PubMed ID: 19494268
[TBL] [Abstract][Full Text] [Related]
18. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
Chan CT; Reeves RE; Geller R; Yaghoubi SS; Hoehne A; Solow-Cordero DE; Chiosis G; Massoud TF; Paulmurugan R; Gambhir SS
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2476-85. PubMed ID: 22895790
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous Responses and Isoform Compensation the Dim Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer.
Tang X; Chang C; Mosallaei D; Woodley DT; Schönthal AH; Chen M; Li W
Mol Cell Biol; 2022 Feb; 42(2):e0045921. PubMed ID: 34871064
[TBL] [Abstract][Full Text] [Related]
20. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
